Management of diabetic neuropathy with memantine: A randomized clinical trial.

IF 2.8 4区医学 Q3 ENDOCRINOLOGY & METABOLISM

Diabetes & Vascular Disease Research Pub Date : 2023-07-01 DOI:10.1177/14791641231191093

Elnaz Jafarzadeh, Samineh Beheshtirouy, Nasser Aghamohammadzadeh, Saba Ghaffary, Parvin Sarbakhsh, Elnaz Shaseb

{"title":"Management of diabetic neuropathy with memantine: A randomized clinical trial.","authors":"Elnaz Jafarzadeh, Samineh Beheshtirouy, Nasser Aghamohammadzadeh, Saba Ghaffary, Parvin Sarbakhsh, Elnaz Shaseb","doi":"10.1177/14791641231191093","DOIUrl":null,"url":null,"abstract":"Background: Diabetes patients frequently experience diabetic neuropathy (DN), a microvascular complication that significantly reduces patients' quality of life. Memantine has demonstrated potential benefits for neuropathic pains in preclinical studies. This study aimed to assess the efficacy of memantine in the management of peripheral neuropathy in patients with type 2 diabetes mellitus (T2DM).Method: This randomized clinical trial includes 143 diabetic patients (aged between 18 and 75 years) with a confirmed diagnosis of diabetic neuropathy. Patients were randomly assigned to receive memantine 5 mg twice daily for 1 week, followed by 10 mg twice daily plus gabapentin 300 mg daily (n = 72) or just gabapentin 300 mg daily (n = 71) for 8 weeks. The DN4 questionnaire, monofilament, tuning fork, and Tip-therm tests were used to measure neuropathy at baseline and after the 8-week intervention.Results: The mean score of the DN4 questionnaire in the memantine group was significantly lower than the control group (p. value: .001). The number of patients with diabetic neuropathy remarkably decreased in the memantine group at the end of the study based on the performed tests (p. value: .001).Conclusion: Memantine functions as a beneficial agent in the management of diabetic neuropathy, which would significantly improve the quality of life in diabetic patients.","PeriodicalId":11092,"journal":{"name":"Diabetes & Vascular Disease Research","volume":"20 4","pages":"14791641231191093"},"PeriodicalIF":2.8000,"publicationDate":"2023-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/7d/90/10.1177_14791641231191093.PMC10387673.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes & Vascular Disease Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/14791641231191093","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Diabetes patients frequently experience diabetic neuropathy (DN), a microvascular complication that significantly reduces patients' quality of life. Memantine has demonstrated potential benefits for neuropathic pains in preclinical studies. This study aimed to assess the efficacy of memantine in the management of peripheral neuropathy in patients with type 2 diabetes mellitus (T2DM).

Method: This randomized clinical trial includes 143 diabetic patients (aged between 18 and 75 years) with a confirmed diagnosis of diabetic neuropathy. Patients were randomly assigned to receive memantine 5 mg twice daily for 1 week, followed by 10 mg twice daily plus gabapentin 300 mg daily (n = 72) or just gabapentin 300 mg daily (n = 71) for 8 weeks. The DN4 questionnaire, monofilament, tuning fork, and Tip-therm tests were used to measure neuropathy at baseline and after the 8-week intervention.

Results: The mean score of the DN4 questionnaire in the memantine group was significantly lower than the control group (p. value: .001). The number of patients with diabetic neuropathy remarkably decreased in the memantine group at the end of the study based on the performed tests (p. value: .001).

Conclusion: Memantine functions as a beneficial agent in the management of diabetic neuropathy, which would significantly improve the quality of life in diabetic patients.

Abstract Image

查看原文本刊更多论文

美金刚治疗糖尿病神经病变：一项随机临床试验。

背景：糖尿病患者经常经历糖尿病神经病变（DN），这是一种微血管并发症，会显著降低患者的生活质量。美金刚已在临床前研究中证明对神经性疼痛有潜在益处。本研究旨在评估美金刚治疗2型糖尿病（T2DM）患者周围神经病变的疗效。方法：本随机临床试验包括143名确诊为糖尿病神经病变的糖尿病患者（年龄在18至75岁之间）。患者被随机分配接受美金刚5 mg，每日两次，持续1周，然后接受10 mg，每日二次，加加巴喷丁300 mg，持续8周（n=72）或仅接受加巴喷汀300 mg，为期8周。DN4问卷、单丝、音叉和Tip热测试用于测量基线和8周干预后的神经病变。结果：美金刚组DN4问卷的平均得分显著低于对照组（p值：.001）。根据所进行的测试，在研究结束时，美金刚组糖尿病神经病变患者的数量显著减少（p值为.001）。结论：美金刚在糖尿病神经病变的治疗中是一种有益的药物，这将显著改善糖尿病患者的生活质量。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Diabetes & Vascular Disease Research ENDOCRINOLOGY & METABOLISM-PERIPHERAL VASCULAR DISEASE

CiteScore

4.40

自引率

0.00%

发文量

审稿时长

>12 weeks

期刊介绍： Diabetes & Vascular Disease Research is the first international peer-reviewed journal to unite diabetes and vascular disease in a single title. The journal publishes original papers, research letters and reviews. This journal is a member of the Committee on Publication Ethics (COPE)